TICKERNERD
Menu
RAPPRAPPHealthcare · Biotechnology

RAPP Stock Forecast: Rapport Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$46
+0.46% on the day

The 13 Wall Street analysts covering Rapport Therapeutics, Inc. hold a median 12-month price target of $59 — +28.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 8 Sept 2026 — in the lower half.

Market cap
$2.2B
Ticker Nerd rank
46 / 100
Median analyst target
$59
Analysts covering
13
Revenue$0.0
Operating income−$60.8M
Net income−$56.6M
Free cash flow−$41.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.5%
1M
+1.1%
YTD
+51.5%
1Y
+46.1%
From 52W high
−12.4%
From 52W low
+105.3%
$22
$53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RAPP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rapport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
46 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
72
Quality
55
Accruals
54
Issuance
44
Size
35
Revisions
35
Growth
30
Volatility
30

Momentum (98): The shares have been drifting up relative to others.

Volatility (30): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RAPP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RAPP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26RAPPHigh $80Median $59Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $50Median $59High $80

The green dot is the last close — the median target sits +28.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026BTIGReiteratesBuy$65
12 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $66
5 Aug 2026BTIGReiteratesBuy—
5 Aug 2026BTIGReiteratesBuy$65
16 July 2026BTIGReiteratesBuy$65
16 July 2026BTIGReiteratesBuy—
24 June 2026Leerink PartnersInitiatesOutperform$52
24 June 2026Leerink PartnersInitiatesOutperform—
21 May 2026BTIGMaintainsBuy—
19 May 2026Truist SecuritiesAssumesBuy$44 → $56
8 May 2026BTIGReiteratesBuy—
22 Apr 2026BTIGReiteratesBuy—
11 Mar 2026BTIGMaintainsBuy—
11 Mar 2026Wells FargoMaintainsOverweight—
2 Feb 2026Wells FargoInitiatesOverweight—
9 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025BTIGReiteratesBuy—
19 Nov 2025BTIGInitiatesBuy—
7 Nov 2025CitizensMaintainsMarket Outperform—
16 Sept 2025Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RAPP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RAPP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, Rapport Therapeutics, Inc. returned +46.1% against +19.4% for the S&P 500, dividends included.

RAPP vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26RAPPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RAPP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Rapport Therapeutics, Inc. (RAPP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.2×

Cheaper than 36% of US stocks

Price / sales
110.6×

Cheaper than 4% of US stocks

Price / book
5.2×

Cheaper than 20% of US stocks

EV / EBITDA
−11.7×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−767.6%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−40.0%

Higher than 24% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rapport Therapeutics, Inc. (RAPP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rapport Therapeutics, Inc. has a market value of $2.2B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $20.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$137.2M, a −685.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.04.

  • Free cash flow in the twelve months to 30 June 2026: −$97.1M.

  • Rapport Therapeutics, Inc. spent $5K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 48.0M.

  • Trailing P/E: 21.2×; forward P/E: −8.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Rapport Therapeutics, Inc. employs 84 people — $238K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Sept 2026

Data provided by Twelve Data

Peers

RAPP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RAPPRapport Therapeutics, Inc.$2.2B
46
URGNUroGen Pharma Ltd.$2.1B
80
ADMAADMA Biologics, Inc.$2.1B
42
AUPHAurinia Pharmaceuticals, Inc.$2.1B
93
BHVNBiohaven Ltd.$2.1B
34
KODKodiak Sciences, Inc.$2.1B
43
ZBIOZenas BioPharma, Inc.$2.1B
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rapport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RAPP news & analysis

Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Rapport Therapeutics announced that its management plans to participate in upcoming investor conferences, including a fireside chat at the Cantor Global Healthcare Conference in New York City on Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm focused on developing small molecule precision medicines for neurological and psychiatric disorders.

Why it matters — A RAPP watcher would be interested because the company's participation in investor conferences provides opportunities for management to communicate with investors about its clinical-stage programs.

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

GlobeNewsWire · 24 Aug 2026neutral

Rapport Therapeutics announced it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET, focusing on the unmet need in bipolar mania and the company's RAP-219 clinical program. The event is open to registration.

Why it matters — RAPP watchers would care because the event will provide insight into the unmet need in bipolar mania and the clinical development of RAP-219, a key pipeline program for the company.

Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise

Seeking Alpha · 21 Aug 2026positive

Seeking Alpha discusses Rapport Therapeutics' lead candidate RAP-219, highlighting its neuroanatomically selective pharmacology and a 22-day half-life that offers a forgiveness advantage for missed doses. The report notes RAPP has $436.1M in cash expected to last into 2H 2029, fully funding pivotal Phase 3 trials, though it will likely need additional capital before commercial launch. Regulatory scrutiny is expected regarding safety during prolonged exposure.

Why it matters — A RAPP watcher would care because the piece highlights RAP-219's differentiated pharmacology and long half-life as a potential franchise-building advantage, while flagging the company's future capital needs and anticipated regulatory scrutiny on long-term safety.

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

GlobeNewsWire · 5 Aug 2026positive

Rapport Therapeutics reported financial results for the quarter ending June 30, 2026, having initiated the RAP-219 Phase 3 program in focal onset seizures with FOCUS 1 and FOCUS 2 trials now enrolling patients. The company held $436.1 million in cash, cash equivalents and short-term investments, expected to fund operations into the second half of 2029, and noted ongoing pipeline progress across RAP-219 and RAP-641.

Why it matters — A Rapport watcher would care because the company is advancing its lead RAP-219 program into Phase 3 with a Phase 2 bipolar mania topline expected in October 2026, and holds a cash runway into the second half of 2029 to support that work.

FAQ

Frequently asked questions about RAPP stock

What is the RAPP stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Rapport Therapeutics, Inc. have a median 12-month price target of $59, with estimates ranging from $50 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RAPP stock a buy right now?

Of the 13 analysts covering Rapport Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapport Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RAPP?

As at 8 Sept 2026, Rapport Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will RAPP stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +28.3% from the last close, and Ticker Nerd's factor model ranks Rapport Therapeutics, Inc. 46 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RAPP stock forecast for 2030?

No analyst covering Rapport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RAPP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $80 over the next 12 months.

How has RAPP stock performed over the past year?

Rapport Therapeutics, Inc. returned +46.1% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rapport Therapeutics, Inc. do?

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders.

What is the latest news on RAPP?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Rapport Therapeutics to Participate in Upcoming Investor Conferences". Rapport Therapeutics announced that its management plans to participate in upcoming investor conferences, including a fireside chat at the Cantor Global Healthcare Conference in New York City on Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm focused on developing small molecule precision medicines for neurological and psychiatric disorders.

Company

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. The company’s work centers on precision neuroscience, using its RAP technology platform to target receptor-associated proteins that help regulate neuronal signaling. Its pipeline includes investigational programs for focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, migraine, and hearing or vestibular disorders. Rapport Therapeutics also develops receptor-targeted candidates in areas such as AMPA receptor modulation and nicotinic acetylcholine receptor biology, reflecting a broad research effort across neurological and psychiatric conditions. Headquartered in Boston, Massachusetts, Rapport Therapeutics plays a specialized role in the biotechnology market by advancing targeted therapies designed for complex brain and nervous system diseases.

CEO Mr. Abraham N. Ceesay M.B.A. · 84 employees · United States · https://www.rapportrx.com